Where to get peptides safely: the three routes, ranked by oversight

“Where do I get peptides?” is the wrong first question. The better one is how much oversight stands between me and the vial — because that single variable decides whether you know what is in it, whether anyone is accountable for your care, and whether the dose on the label means anything. There are essentially three routes to a peptide in 2026, and they are not equivalent. This guide ranks them by oversight, explains what each one actually involves, and is honest about the one most peptides are sold through — the unregulated gray market — without teaching you how to navigate it. The goal here is to steer toward the legitimate routes and to make the risks of the alternative legible.

Route 1: FDA-approved peptide drugs (highest oversight)

A surprising number of “peptides” people search for have FDA-approved cousins that are already on pharmacy shelves. Tesamorelin (Egrifta) is an approved growth-hormone– releasing analog; bremelanotide (Vyleesi) is an approved melanocortin-receptor agonist delivered by subcutaneous injection;^[10] and the GLP-1 receptor agonist semaglutide is an approved peptide drug used at scale. When a peptide reaches this tier, it has cleared the whole apparatus: human trials, a defined indication, and manufacturing under current Good Manufacturing Practice (cGMP) — meaning identity, purity and the actual quantity per dose are verified, lot to lot. You get it the ordinary way: a clinician diagnoses a condition the drug is approved for and writes a prescription. The trade-off is that the menu is short and the indications are specific — you cannot get an approved drug for an off-list “biohacking” goal. But for anything in this tier, this is unambiguously the safest way to obtain it. Our weight-loss peptide evidence guide covers where the approved GLP-1 drugs actually have data behind them.

Route 2: compounded peptides from a licensed pharmacy (real prescription required)

Many popular peptides are not sold as finished, approved drugs — the legitimate middle route for some of them is compounding, where a licensed pharmacy prepares a medication for an individual patient against a valid prescription. This is the route behind reputable telehealth offerings for things like sermorelin. The crucial detail is who is allowed to compound and from what.

Two regulatory categories define this space, and the difference is worth understanding before you trust a source.^[1]

A 503A pharmacy is your traditional, state-board-licensed compounding pharmacy that prepares a drug for one patient against that patient’s prescription. A 503B outsourcing facility registers directly with the FDA, is inspected against cGMP-style standards, and can produce batches for clinics — a higher tier of oversight.^[1] Either way, two things are non-negotiable: the pharmacy is licensed, and there is a real prescription from a clinician who evaluated you. A “pharmacy” that ships injectables with neither is not compounding — it is the gray market wearing a lab coat.

The catch: FDA limits which peptides can be compounded

Here is where a lot of marketing quietly misleads people. A licensed pharmacy cannot compound from any substance it likes. The FDA maintains category lists for bulk drug substances nominated for use in compounding under sections 503A and 503B. The agency sorts nominated substances into categories: Category 1 substances may be eligible and the FDA does not intend to act against their use pending evaluation; Category 2 substances are those for which the FDA has identified significant safety risks; and Category 3 substances were nominated with insufficient information to evaluate.^[1]

Several of the most-hyped peptides have not cleared this bar. As of the FDA’s current lists, BPC-157 sits in Category 2 — the agency states that compounded drugs containing BPC-157 may pose a risk of immunogenicity for certain routes of administration and may carry complexities around peptide-related impurities and active-ingredient characterization.^[2] In plain terms: a legitimate compounding pharmacy generally should not be making BPC-157 for you, and a source that offers it freely is signaling that it is operating outside that framework. (For why the dosing claims around it are also unsupported, see our BPC-157 dosage and safety and BPC-157 side effects explainers.) The same caution applies to other injectables marketed for “recovery” or “regeneration” — reviews of injectable peptides in sports and regenerative settings stress that these are largely unapproved, inconsistently sourced products used outside any clinical framework.^[7] Before trusting a compounded source, the honest move is to check the substance’s current status on FDA.gov rather than take a vendor’s word.

Route 3: “research use only” gray-market vendors (no oversight)

This is where most peptides are actually sold, and it is the route with no oversight at all. The product is labeled “research use only” or “not for human consumption,” which is a legal fiction that lets a vendor sidestep drug regulation while still implicitly selling for human use — often with dosing instructions a click away. There is no prescription, no licensed pharmacy, no clinician, and critically no manufacturing standard. The label is a marketing claim, not an assay.

The evidence on what is actually in these products is consistent and unflattering. A 2024 market-surveillance study of semaglutide sold online without a prescription evaluated purchased products and documented serious quality and safety problems across vendors.^[3] Analytical work on melanotan II tanning products sold illegally on the internet used LC-UV-MS/MS to characterize what buyers received — finding products that did not match their labeling.^[4] A study of supplements marketed to UK consumers as containing selective androgen receptor modulators found frequent mislabeling: substances present that were not declared, and declared substances absent or under-dosed.^[5] Broader reviews of the falsification of biotechnology and peptide drugs describe this as a present danger, not a hypothetical one,^[6] and qualitative work on the online market for image- and performance-enhancing drugs documents exactly the trust gap buyers operate inside — they cannot verify what they are buying.^[8] The downstream harm is real: melanotan II injection has been linked to systemic toxicity and rhabdomyolysis in published case reports.^[9] When you cannot confirm identity, purity or dose, “how much should I take” has no answerable meaning — a theme we return to across our peptide coverage, from TB-500 to PT-141.

The red flags that should end the transaction

• An injectable sold with no prescription required. A legitimate route to an injectable peptide runs through a clinician and a licensed pharmacy. “Add to cart” for an injectable is the single biggest red flag.
• “Research use only” or “not for human consumption” — sold next to dosing instructions. This contradiction is the gray market’s whole business model. It is a disclaimer designed to dodge regulation, not to protect you.
• No third-party certificate of analysis (CoA). And where a CoA is shown, it should be from an independent lab, batch-specific, and verifiable — not a generic image. Given how often analyses find mislabeled product,^[5] an unverifiable CoA is worth little.
• A substance the FDA has flagged, offered freely. If a “pharmacy” will compound a Category 2 substance like BPC-157 without hesitation,^[2] it is telling you it does not follow the rules a real pharmacy follows.
• No licensed clinician and no accountable pharmacy. If no named, licensed professional is responsible for the prescription and the product, no one is accountable for what happens to you.

The honest bottom line

Rank your options by oversight and the decision gets simple. If the peptide you want exists as an FDA-approved drug, get it that way — the dose is known and the manufacturing is verified.^[10] If it is legitimately available through compounding, use a licensed 503A or 503B pharmacy with a real prescription, and confirm the substance is actually permitted rather than sitting in FDA’s Category 2.^[1][2] If your only path is a “research use only” vendor, understand that you are buying outside every safeguard, into a market where independent analyses keep finding mislabeled and contaminated product.^[3][4][6] A premium, evidence-first read does not hand you a sourcing map for that last route — it points you to the first two, and is honest that the third is a gamble on a vial whose contents no one will vouch for. To pressure-test the evidence behind a specific peptide before you spend anything, start with our peptide evidence matrix, and if you are evaluating clinical providers, our editors’ peptide therapy roundup ranks the legitimate, prescription-based options.